Imfinzi reduced the risk of distant metastases and death from bladder cancer vs. neoadjuvant chemotherapy alone
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Utidelone can penetrate BBB due to its unique physicochemical characteristics and insusceptibility to P-glycoprotein-mediated efflux
Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer
Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
